Clinical trial
Safety and Tolerability Study of Drug to Treat Schizophrenia
NCT00044005 · Sumitomo Pharma America, Inc., Industry · Completed
Key facts
| NCT number | NCT00044005 |
|---|---|
| Title | Safety and Tolerability Study of Drug to Treat Schizophrenia |
| Official title | A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 (Lurasidone) in Patients With Schizophrenia |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg |
| Enrollment | 98 |
| Start date | Sep 1, 2002 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Aug 20, 2002 |
| Last update posted | Apr 17, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: